TNM app – your digital support for lung cancer classification
The TNM app created by AstraZeneca GmbH offers you a compact overview of the current TNM classifications of lung cancer. A suitable training material for the 7th, 8th and 9th editions of the TNM classification.
Main functions:
• Comprehensive TNM classification: The app contains the 7th, 8th and 9th editions of the IASLC (International Association for the Study of Lung Cancer) TNM classification and provides detailed information on tumor stages, lymph nodes and metastases in lung cancer.
• Resectability in lung cancer: current information on the resectability of NSCLC
• Lymph node map: A detailed map to determine the N classification.
• User-friendly and precise:
With clearly structured information and interactive graphics, the TNM app provides accessible information about the TNM classification.
Improve your knowledge with the TNM app for lung cancer.
Note: The app is intended exclusively for healthcare professionals. The app is intended exclusively as a training opportunity for the TNM classification published by the IASLC and for comparing literature. It does not constitute medical advice and is not suitable or intended for diagnosis or treatment decisions. No patient data can be processed in the app.
She is responsible
AstraZeneca GmbH,
Friesenweg 26,
22763 Hamburg
Managing Director: Alexandra Bishop
Commercial register: AG Hamburg HRB 175066
VAT ID number: DE143080460
Responsible for the purposes of the press and according to Section 18 Paragraph 2 MStV:
Sabine Reinstädler (address as above)
Telephone: 040-8090 34100
Email:
[email protected]
Competent supervisory authority
Authority for Justice and Consumer Protection (BJV)
Office of Consumer Protection
Pharmacy and Medical Devices Department
PO Box 30 28 22, D-20310 Hamburg
Please report suspected cases of side effects of our products to Patient Safety within 24 hours: https://contactazmedical.astrazeneca.com/
Email:
[email protected]
Telephone: 0800 22 88 660
Release number: DE-81143/04-25